• 1 State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 North Lishi Road, Beijing 100037, China
  • 2 Medanta, The Medicity Hospital, Sector 38, Gurgaon, Haryana 122041, India
  • 3 Instituto de Cardiologia - Fundacion Cardioinfantil, Centro Internacional de Arritmias Calle 163 A #13B- 60, Bogota, Colombia
  • 4 Republican Scientific Practical Centre Cardiology, R. Luxembourg Str. 110, Minsk 220036, Belarus
  • 5 Institut Jantung Negara, 145 Jalan Tun Razak, Kuala Lumpur 50400, Malaysia
  • 6 National Heart Centre Singapore, 5 Hospital Avenue, Singapore 169609, Singapore
  • 7 West China Hospital, Sichuan University, No. 37 Guo Xue St., Chengdu 610041, China
  • 8 Cardiovascular Center, 5/F, National Taiwan University Hospital, No. 7, Chung Shan S. Rd, Zhong Zheng District, Taipei City 10002, Taiwan
  • 9 Medtronic, CRHF Clinical Research, 8200 Coral Sea Street NE, Mounds View, Minneapolis, MN 55112, USA
  • 10 Korea University Medical Center, A126-1 5th St. Anam-dong Sungbuk-ku, Seoul 136-705, Korea
Europace, 2015 Nov;17(11):1720-6.
PMID: 26037794 DOI: 10.1093/europace/euv103


This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.